Delcath Systems (DCTH) reported second-quarter 2026 revenue of $29.1 million, up from $24.2 million a year earlier, and net income of $2.7 million. The company also raised its 2026 revenue guidance to a range of $104 million to $108 million.
The interventional oncology company reported 90% gross margins, $5.7 million in cash provided by operations for the quarter, and $95.9 million in cash and investments as of June 30, 2026.
- Total revenue was $29.1 million, compared with $24.2 million in the second quarter of 2025.
- HEPZATO KIT revenue was $27.1 million, while CHEMOSAT revenue was $2.0 million.
- Net income was $2.7 million for both the second quarters of 2026 and 2025.
- Non-GAAP adjusted EBITDA was $7.6 million, compared with $9.8 million a year earlier.
- Delcath reported 31 active treatment centers and approximately 30% growth in HEPZATO volume versus the prior-year quarter.
- Full-year 2026 revenue guidance was increased to $104 million to $108 million.
$DCTH Insider Trading Activity
$DCTH insiders have traded $DCTH stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $DCTH stock by insiders over the last 6 months:
- SANDRA PENNELL (Chief Financial Officer) purchased 5,533 shares for an estimated $50,018
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$DCTH Hedge Fund Activity
We have seen 63 institutional investors add shares of $DCTH stock to their portfolio, and 47 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PROPEL BIO MANAGEMENT, LLC added 541,189 shares (+123.4%) to their portfolio in Q1 2026, for an estimated $5,022,233
- EXODUSPOINT CAPITAL MANAGEMENT, LP removed 460,737 shares (-92.8%) from their portfolio in Q1 2026, for an estimated $4,275,639
- MILLENNIUM MANAGEMENT LLC added 341,611 shares (+138.6%) to their portfolio in Q1 2026, for an estimated $3,170,150
- PRIVATE WEALTH ADVISORS, LLC added 301,043 shares (+103.6%) to their portfolio in Q1 2026, for an estimated $2,793,679
- GOLDMAN SACHS GROUP INC removed 298,547 shares (-50.8%) from their portfolio in Q1 2026, for an estimated $2,770,516
- CITADEL ADVISORS LLC removed 291,601 shares (-79.1%) from their portfolio in Q1 2026, for an estimated $2,706,057
- RENAISSANCE TECHNOLOGIES LLC removed 206,299 shares (-57.1%) from their portfolio in Q1 2026, for an estimated $1,914,454
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
